ReviewNature reviews. Gastroenterology & hepatology2017
Regenerative medicine and cell-based approaches to restore pancreatic function.
Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 101 citations in OpenAlex.
- E12.5 pancreatic bud-derived cells are detected in recipient pancreata after intraplacental transplantation, but Pdx1-deficient recipients lack a macroscopically detectable pancreas.Scientific reports · 2026Article
- Article
- miR-302 regulates pancreatic progenitor pool and pancreatic size.Biology open · 2026Article
- Human embryonic stem cell-derived Sertoli cells as an immune modulator of cell transplantation therapy in a diabetic mice model.Stem cell research & therapy · 2025Article
- Improving cellular fitness of human stem cell-derived islets under hypoxia.Nature communications · 2025Article
- Scaffold-free endocrine tissue engineering: role of islet organization and implications in type 1 diabetes.BMC endocrine disorders · 2025Review
- Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease.bioRxiv : the preprint server for biology · 2023Article
- miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.International journal of molecular sciences · 2022Review
- Nanoparticle encapsulated CQ/TAM combination harmonizes with MSCs in arresting progression of severity in AP mice through iNOS (IDO) signaling.Materials today. Bio · 2022Article
- Mature but not developing Schwann cells promote axon regeneration after peripheral nerve injury.NPJ Regenerative medicine · 2022Article
- The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis.Frontiers in oncology · 2022Review
- Construction of 3D hierarchical tissue platforms for modeling diabetes.APL bioengineering · 2021Review
- Article
- Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications.World journal of stem cells · 2021Review
- Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells.International journal of molecular sciences · 2020Review
- Bioprinting: From Tissue and Organ Development toChemical reviews · 2020Review
- Engineering designer beta cells with a CRISPR-Cas9 conjugation platform.Nature communications · 2020Article
- Characterizing pancreatic β-cell heterogeneity in the streptozotocin model by single-cell transcriptomic analysis.Molecular metabolism · 2020Article
- Direct Lineage Reprogramming: Harnessing Cell Plasticity between Liver and Pancreas.Cold Spring Harbor perspectives in biology · 2020Review
- circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.Molecular cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pancreas is a complex organ with exocrine and endocrine components. Many pathologies impair exocrine function, including chronic pancreatitis, cystic fibrosis and pancreatic ductal adenocarcinoma. Conversely, when the endocrine pancreas fails to secrete sufficient insulin, patients develop diabetes mellitus. Pathology in either the endocrine or exocrine pancreas results in devastating economic and personal consequences. The current standard therapy for treating patients with type 1 diabetes mellitus is daily exogenous insulin injections, but cell sources of insulin provide superior glycaemic regulation and research is now focused on the goal of regenerating or replacing β cells. Stem-cell-based models might be useful to study exocrine pancreatic disorders, and mesenchymal stem cells or secreted factors might delay disease progression. Although the standards that bioengineered cells must meet before being considered as a viable therapy are not yet established, any potential therapy must be acceptably safe and functionally superior to current therapies. Here, we describe progress and challenges in cell-based methods to restore pancreatic function, with a focus on optimizing the site for cell delivery and decreasing requirements for immunosuppression through encapsulation. We also discuss the tools and strategies being used to generate exocrine pancreas and insulin-producing β-cell surrogates in situ and highlight obstacles to clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.